The semaglutide vs tirzepatide comparison page covers the broader differences beyond just dosing
Regarding mortality, a total of 16 deaths were reported in semaglutide treatment groups, 8 deaths were reported in active comparator groups (empagliflozin, sitagliptin, liraglutide, and dulaglutide), and 3 deaths were reported in placebo groups
Zepbound has also been shown to improve related cardiometabolic markers, including reductions in blood pressure, cholesterol, and visceral fat in people with obesity
Tirzepatide has quickly become one of the most talked-about medications for diabetes and weight management since its first approval in 2022, but it can also be expensive
Meaning they are both extremely important for our bodies, almost like joint gold medal winners